<DOC>
	<DOCNO>NCT00133302</DOCNO>
	<brief_summary>The purpose trial investigate clinical benefit dose intensified regimen , Bi-CHOP comparison standard CHOP advance intermediate high grade non-Hodgkin 's lymphoma ( NHL ) .</brief_summary>
	<brief_title>Study Standard CHOP Versus Biweekly CHOP Aggressive Non-Hodgkin 's Lymphoma ( JCOG9809 )</brief_title>
	<detailed_description>The purpose JCOG9809 determine whether treatment result aggressive NHL could improve shortening interval CHOP chemotherapy prophylactic use G-CSF . The primary endpoint Progression Free Survival ( PFS ) , plan accrual 450 . Until December , 2002 , 323 patient advanced aggressive NHL randomize standard CHOP arm ( CHOP x 8 , every three week ) biweekly CHOP arm ( CHOP x 8 , every two week ) .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>Intermediate highgrade nonHodgkin 's lymphoma , exclude cutaneous tcell lymphoma ( CTCL ) , adult Tcell leukemialymphoma ( ATL ) Tcell lymphoblastic lymphoma ( TLbL ) ( Working Formulation ) Ann Arbor stage : II , III , IV No prior chemotherapy radiotherapy Age : 15 69 Performance status ( PS ) : 0 , 1 , 2 WBC &gt; = 3,000 /mm3 , ANC &gt; = 1,200 /mm3 , Platelet &gt; = 75,000 /mm3 GOT/GPT &lt; = 5 x Normal Upper Limit , TBil &lt; = 2.0 mg/dL Creatinine &lt; = 2.0 mg/dL Normal ECG , Ejection Fraction &gt; = 50 % PaO2 &gt; = 65 mmHg Written inform consent Uncontrollable diabetes mellitus Severe complication ( infection , heart failure , renal failure , liver failure , etc ) Anamnesis heart disease Acute chronic hepatitis , liver cirrhosis portal hypertension Synchronous metachronous malignancy Severe pulmonary dysfunction Central nervous system ( CNS ) invasion HIV positive Hepatitis B surface antigen ( HBsAg ) positive Hepatitis C virus antibody ( HCVAb ) positive</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>Non-Hodgkin 's lymphoma</keyword>
	<keyword>intermediate-grade lymphoma</keyword>
	<keyword>high-grade lymphoma</keyword>
	<keyword>CHOP protocol</keyword>
	<keyword>granulocyte-colony stimulating factor</keyword>
</DOC>